Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Piper Jaffray Keeps Biogen at Market Perform


Piper Jaffray keeps Biogen Idec (BIIB) at market perform.

Analyst Mark E. Karvosky says Biogen Idec and Elan reported its first case of PML in a patient receiving monotherapy Tysabri.

He reminds investors this is third case of PML (progressive ultifocal leukoencephalopathy) overall. The other two cases occurred in patients receiving Tysabri and an Avonex combo therapy.

Karvosky says the news is clearly negative and complicates predictions about when and if Tysabri will return to the market. But his estimates for Biogen don't include any Tysabri revenue so while he expects the stock to remain volatile over the next few quarters, he would be a buyer under $36. He maintains his $42 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus